The use of hypomethylating agents in hematologic malignancies: treatment peferences and result

Basit Öğe Kaydı
dc.authoridMehmet Hilmi Doğu / 0000-0001-7237-2637en_US
dc.authorscopusidMehmet Hilmi Doğu / 55212747300
dc.authorwosidMehmet Hilmi Doğu / W-2255-2017en_US
dc.contributor.authorDoğu, Mehmet Hilmi
dc.contributor.authorSerin, İstemi
dc.date.accessioned2022-05-20T09:50:01Z
dc.date.available2022-05-20T09:50:01Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.description.abstractAim: The objective of this article was to compare the efficiency of azacitidine (AZA) and decitabine (DAC) in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) who are not suitable for high-dose chemotherapy. Materials and methods: MDS and AML patients who were treated with hypomethylating agents (HMAs) between January 2005 and 2020 were evaluated retrospectively. Results: No statistically significant difference was found between the patients who received AZA or DAC in AML patients. In MDS group, the rate of patients who achieved remission was statistically significantly higher in patients who received DAC (p = 0,032). Conclusion: The advantage in terms of response for MDS and no survival difference between AZA and DAC for AML and MDS patients will be an important contribution to the literature. First draft submitted: 24 August 2020; Accepted for publication: 6 September 2021; Published online: 12 November 2021en_US
dc.identifier.citationSerin I, Dogu MH. The use of hypomethylating agents in hematologic malignancies: treatment preferences and results. Int J Hematol Oncol. 2021 Nov 12;10(4):IJH37. doi: 10.2217/ijh-2020-0019. PMID: 35295753; PMCID: PMC8922247.en_US
dc.identifier.doi10.2217/ijh-2020-0019en_US
dc.identifier.issn2045-1407en_US
dc.identifier.issue4en_US
dc.identifier.pmid35295753en_US
dc.identifier.urihttp://doi.org/10.2217/ijh-2020-0019
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2677
dc.identifier.volume12en_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorDoğu, Mehmet Hilmi
dc.language.isoenen_US
dc.publisherInternational Journal of Hematologi Oncologyen_US
dc.relation.ispartofInternational Journal of Hematologi Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHypomethylating Agents (HMAs)en_US
dc.subjectDecitabine (DAC)en_US
dc.subjectAzacitidine (AZA)en_US
dc.subjectMyelodysplastic Syndrome (MDS)en_US
dc.subjectAcute Myeloid Leukemia (AML)en_US
dc.titleThe use of hypomethylating agents in hematologic malignancies: treatment peferences and resulten_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
ijh-10-37.pdf
Boyut:
256.25 KB
Biçim:
Adobe Portable Document Format
Açıklama:
makale dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu